Key players in the market include Novo Nordisk, Eli Lilly, Sanofi, Boehringer Ingelheim, AstraZeneca, Merck & Co., Bristol-Myers Squibb, and Amgen
As their popularity surged, drug manufacturers struggled to keep up with demand, especially for Wegovy, the weight lossspecific formulation of semaglutide
People with GI sensitivity If you have a history of GI issues, whether from previous GLP-1 agonist use, conditions like IBS or GERD, or general digestive sensitivity, starting at the absolute lowest dose is critical
Reinforcing this trend, a recent casecontrol study emphasized a robust inverse connection between adiponectin and T scores in women with osteoporosis and osteopenia [93]
Patients should be advised to contact their healthcare provider if gastrointestinal symptoms are severe or persistent, as dose adjustment may be necessary